# Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients

> **NCT03332329** · PHASE4 · UNKNOWN · sponsor: **Qin Ning** · enrollment: 15 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Granulocyte Macrophage Colony Stimulating Factor
- **DRUG:** Y peginterferon alfa-2b
- **DRUG:** HBV vaccine

## Key facts

- **NCT ID:** NCT03332329
- **Lead sponsor:** Qin Ning
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332329, "Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03332329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*